KR20110106826A - Screening method of human papillomavirus antibody using fusion polypeptide hpv antigen - Google Patents

Abstract

The present invention relates to an HP antibody screening method using a fusion polypeptide HPV antigen, wherein the amino acid sequence of glutathione S-transferase (GST) at the N-terminus or Simian virus 40 large T antigen ( simian virus 40 large T-antigen) or an active fragment thereof and the amino acid sequence of HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or active fragment thereof A fusion polypeptide, a method for detecting an HPV antibody in a sample using the fusion polypeptide HPV antigen, and a HPV antibody detection kit for a bead array containing the fusion polypeptide HPV antigen. Using the present invention, it is possible to isolate and purify recombinant HPV antigens with high purity and effectively and uniformly attach them to beads for beads array without affecting the activity that can specifically bind to HPV antibodies. Internal HPV 6, 11, 16 and 18 antibodies can be detected in combination. The antibody titer can be used to determine the inoculation time of the HPV vaccine, and can be used to measure the duration of defense after vaccination.

Description

Screening method of Human Papillomavirus antibody using fusion polypeptide HPV antigen}

The present invention provides an antibody screening method for HPV using a fusion polypeptide HPV antigen, comprising: an amino acid sequence of glutathione S-transferase (GST) at its N-terminus or an active fragment thereof; The amino acid sequence of an Simian virus 40 large T antigen (SV 40 large T-antigen) at its C terminus or an active fragment thereof; And a fusion polypeptide comprising an amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or an active fragment thereof, the fusion polypeptide HPV antigen in a sample A method for detecting an HPV antibody and an HPV antibody detection kit for a bead array comprising the fusion polypeptide HPV antigen.

Every two minutes, one woman dies of cervical cancer worldwide. Cervical cancer, which occurs worldwide annually, is the second most common cancer among women worldwide, affecting about half a million people each year, and among women, the third leading cause of cancer deaths after breast and lung cancer. Human Papillomavirus (HPV) infections are found in more than 99% of cervical cancers, including more than 100 HPVs, 30-40 of which cause mucosal tissue infections, and low-risk HPVs. And carcinogenic HPV. Most importantly, there are more than 15 carcinogenic HPVs that are directly linked to cervical cancer. Of these carcinogenic HPVs, 16 and 18 are the most important and are found in more than 70% of cervical cancers worldwide. Most HPV infections usually heal naturally within six months to two years, but persistent infection with carcinogenic HPV can lead to cervical cancer.

Since the types of HPV subtypes have racial, geographical and environmental characteristics, it is necessary to know the specific subtype status of the country in developing vaccines, and it is necessary to develop Korea's own vaccines using many subtypes that occur in Korea. In the development of the system, it is essential that a technical system be established to measure the immunogenicity of the vaccine. To investigate the maintenance and efficacy of antibodies after HPV vaccinations, such as Gardasil (Merck) and Cervarix (GSK), which have been developed to date, and the timing of vaccine administration, the titers of antibodies produced against these HPV subtypes in serum are measured. It is important to measure. However, no technique has yet been established to simultaneously measure immunogenicity against these vaccines.

Accordingly, the present inventors have endeavored to establish an HPV antibody screening technique capable of measuring the immunogenicity of the vaccine. As a result, the amino acid sequence of glutathione S-transferase (GST) at the N-terminus of HPV antigen or its activity By fusion with the fragment, the amino acid sequence of the simian virus 40 large T-antigen at its C terminus, or an active fragment thereof, the fragment can be recombined without affecting the activity of binding specifically to the HPV antibody. The present invention has been accomplished by discovering that HPV antigens can be isolated and purified in high purity and effectively and uniformly attached to beads for bead arrays to screen HPV antibodies in samples with high sensitivity and accuracy.

An object of the present invention is an amino acid sequence of glutathione S-transferase (GST) at its N terminus or an active fragment thereof; The amino acid sequence of the simian virus 40 large T-antigen at its C terminus or an active fragment thereof; And an amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen, and HPV18 L1 antigen, or an active fragment thereof.

Another object of the present invention is to provide a polynucleotide encoding the fusion polypeptide, an expression vector comprising the polynucleotide, and a transformant transformed with the expression vector.

Another object of the present invention is to bind the fusion polypeptide to the beads for beads array; Reacting the beads to which the fusion polypeptide is bound with a sample; Reacting the sample with a marker labeled secondary antibody; Reacting the secondary antibody with a specific binding agent of the marker to which a fluorescent substance is attached; And detecting the HPV antibody in the sample by measuring the fluorescence value derived from the bead and the fluorescence value derived from the specific binding agent of the marker. In addition, to provide a bead array HPV antibody detection kit comprising the fusion polypeptide.

In one embodiment, the invention provides an amino acid sequence of glutathione S-transferase (GST) at its N terminus or an active fragment thereof; The amino acid sequence of the simian virus 40 large T-antigen at its C terminus or an active fragment thereof; And an amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen, or an active fragment thereof. The amino acid sequence of the fusion polypeptide may be an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-14. The length of the active fragment is not limited, but according to a specific embodiment of the present invention, the length of the Simian virus 40 large T antigen active fragment may be 11 amino acids.

The amino acid sequence of glutathione S-transferase (GST) at its N terminus or an active fragment thereof, the amino acid sequence of simian virus 40 large T-antigen at C terminus or By fusion with active fragments thereof, recombinant HPV antigens can be isolated and purified in high purity and effectively uniformly attached to beads for bead arrays without affecting the ability to specifically bind HPV antibodies. The virus 40 large T antigen can be used to determine whether the recombinant HPV antigen is well attached to the beads, whether the amount of attachment is always the same, and whether the degree of attachment to the beads between the four HPV antigens is uniform. HPV antibodies in the samples can be screened.

In addition, the amino acid sequence and one or more amino acid residues may include a polypeptide having a different sequence. Amino acid exchanges in proteins and polypeptides that do not alter the activity of the molecule as a whole are known in the art. The most commonly occurring exchanges are amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Exchange between Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly. In addition, the protein may include a protein having increased structural stability or increased protein activity against heat, pH, etc. of the protein by variation or modification on the amino acid sequence.

The fusion polypeptides of the present invention may be prepared by chemical peptide synthesis methods known in the art, or may be synthesized in a frame after amplifying genes encoding respective sites by PCR (polymerase chain reaction) or by known methods. It can be linked to the expression vector operatively linked to the clone can be expressed.

In another aspect, the present invention provides a polynucleotide encoding the fusion polypeptide, an expression vector comprising the polynucleotide, and a transformant transformed with the expression vector.

The polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof may be obtained by cleaving a double-stranded polynucleotide consisting of SEQ ID NO: 1 and SEQ ID NO: 2 with Sal I and Not I restriction enzymes.

The polynucleotide encoding the amino acid sequence of the HPV 6 L1 antigen or an active fragment thereof is obtained by digesting a polynucleotide amplified from the HPV 6 genome using a primer set of SEQ ID NO: 3 and SEQ ID NO: 4 with Eco RI and Sal I restriction enzymes. It may be.

The polynucleotide encoding the amino acid sequence of the HPV 11 L1 antigen or an active fragment thereof is a polynucleotide Eco RI and Sal I restriction enzyme amplified from the HPV 11 genome using a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 Can be.

The polynucleotide encoding the amino acid sequence of the HPV 16 L1 antigen or an active fragment thereof is a polynucleotide Bgl II and Sal I restriction enzyme amplified from the HPV 16 genome using a primer set of SEQ ID NO: 7 and SEQ ID NO: 8 Can be.

The polynucleotide encoding the amino acid sequence of the HPV 18 L1 antigen or an active fragment thereof is a polynucleotide Eco RI and Sal I restriction enzyme amplified from the HPV 18 genome using a primer set of SEQ ID NO: 9 and SEQ ID NO: 10 Can be.

In an embodiment of the present invention, the polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof is inserted into the expression vector pGEX 4T-3 digested with restriction enzymes Sal I and Not I to mpGEX 4T-. 3, a step of preparing the vector, cleaving the mpGEX 4T-3 vector with restriction enzymes Eco RI, Sal I to insert a polynucleotide encoding the amino acid sequence of the HPV 6 L1 antigen or an active fragment thereof to obtain a cleavage map of FIG. To prepare an mpGEX4T-3 / HPV 6 L1 vector, transforming the mpGEX4T-3 / HPV6 L1 vector into Escherichia coli BL21 Gen-X ^™ , and a fusion polynucleotide comprising an HPV 6 L1 antigen from the transformant. Obtaining the peptide may produce a fusion polypeptide comprising the HPV 6 L1 antigen.

In addition, in an embodiment of the present invention, the polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof is inserted into the expression vector pGEX 4T-3 digested with restriction enzymes Sal I and Not I to mpGEX. Preparing a 4T-3 vector; cleaving the mpGEX 4T-3 vector with restriction enzymes Eco RI, Sal I to insert a polynucleotide encoding the amino acid sequence of the HPV 11 L1 antigen or an active fragment thereof and cleavage disclosed in FIG. Preparing an mpGEX4T-3 / HPV 11 L1 vector having a map, transforming the mpGEX4T-3 / HPV11 L1 vector into Escherichia coli BL21 Gen-X ^™ , and a HPV 11 L1 antigen from the transformant. Obtaining the fusion polypeptide can produce a fusion polypeptide comprising the HPV 11 L1 antigen.

In addition, in an embodiment of the present invention, the polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof is inserted into the expression vector pGEX 4T-3 digested with restriction enzymes Sal I and Not I to mpGEX. Preparing a 4T-3 vector; cleaving the mpGEX 4T-3 vector with restriction enzymes Bam HI, Sal I to insert a polynucleotide encoding the amino acid sequence of the HPV 16 L1 antigen or an active fragment thereof; Preparing an mpGEX4T-3 / HPV 16 L1 vector having a map, transforming the mpGEX4T-3 / HPV16 L1 vector into Escherichia coli BL21 Gen-X ^™ , and HPV 16 L1 antigen from the transformant. Obtaining the fusion polypeptide can produce a fusion polypeptide comprising the HPV 16 L1 antigen.

In addition, in an embodiment of the present invention, the polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof is inserted into the expression vector pGEX 4T-3 digested with restriction enzymes Sal I and Not I to mpGEX. Preparing a 4T-3 vector; cleaving the mpGEX 4T-3 vector with restriction enzymes Eco RI, Sal I to insert a polynucleotide encoding the amino acid sequence of the HPV 18 L1 antigen or an active fragment thereof and cleavage disclosed in FIG. Preparing an mpGEX4T-3 / HPV 18 L1 vector with a map, transforming the mpGEX4T-3 / HPV18 L1 vector into Escherichia coli BL21 Gen-X ^™ , and HPV 18 L1 antigen from the transformant. Obtaining the fusion polypeptide can produce a fusion polypeptide comprising the HPV 18 L1 antigen.

Amino acid sequence of glutathione S-transferase (GST) at its N terminus of HPV antigen or active fragment thereof, amino acid sequence of simian virus 40 large T-antigen at C terminus or By fusion with its active fragments, the recombinant HPV antigen can be isolated and purified in high purity and effectively attached uniformly to beads for bead array, and the recombinant HPV antigen adheres well to the beads through the Simian virus 40 large T antigen. It is possible to determine whether the amount is always the same, and whether the degree of adhesion to the beads between the four HPV antigens is uniform, etc., in order to avoid affecting the antigenicity that can specifically bind to HPV antibodies, selection of HPV antigen sites, Both the direction of engagement and the position of engagement should be considered. This is because the presence of the fusion moiety at both ends may cause the site of antigenicity to be immersed in the molecule, thereby reducing the antigenicity. The fusion polypeptide of the present invention is capable of screening HPV antibodies in a sample with high sensitivity and accuracy is an inferior effect.

The polynucleotide sequence may be mutated by one or more bases substituted, deleted, inserted, or a combination thereof. When chemically synthesizing nucleotide sequences, synthetic methods well known in the art may be used, for example, those described in Engels and Uhlmann, Angew Chem Int Ed Eng., 37: 73-127, 1988. , Triester, phosphite, phosphoramidite and H-phosphate methods, PCR and other autoprimer methods, oligonucleotide synthesis on a solid support, and the like.

In the present invention, "operably linked" refers to a functional linkage of a nucleic acid expression control sequence and a nucleic acid sequence encoding a protein or RNA of interest to perform a general function. For example, promoters and nucleic acid sequences encoding proteins or RNAs can be operably linked to affect expression of coding sequences. Operative linkage with expression vectors can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation employs enzymes and the like generally known in the art.

As used herein, an "expression vector" refers to a gene construct that is a recombinant vector capable of expressing a protein of interest in a suitable host cell and includes essential regulatory elements operably linked to express a gene insert. The expression vectors of the present invention include expression control elements such as promoters, operators, initiation codons as elements generally possessed by suitable expression vectors. Initiation and termination codons are generally considered to be part of a nucleotide sequence encoding a polypeptide and must be functional in the individual when the gene construct is administered and must be in frame with the coding sequence. The promoter of the vector may be constitutive or inducible.

It may also include a signal sequence for the release of the fusion polypeptide to facilitate the separation of the protein from the cell culture. Specific initiation signals may also be required for efficient translation of inserted nucleic acid sequences. These signals include ATG start codons and contiguous sequences. In some cases, an exogenous translational control signal must be provided that can include an ATG start codon. These exogenous translational control signals and initiation codons can be various natural and synthetic sources. Expression efficiency can be increased by the introduction of appropriate transcriptional or translation enhancing factors.

As the expression vector, all conventional expression vectors can be used. Depending on the host cell, the expression level and expression of the protein are different. Therefore, the host cell may be selected and used according to the purpose. In an embodiment of the invention, an expression vector comprising a polynucleotide encoding the fusion polypeptide of the invention is an mpGEX4T-3 / HPV6 L1 vector, an mpGEX4T-3 / HPV11 L1 vector, an mpGEX4T-3 / HPV16 L1 vector, mpGEX4T-3 / HPV18 L1 vector was prepared.

When the transformant expressing the vector is cultured in a nutrient medium, a large amount of useful protein can be prepared and separated. The medium and culture conditions may be appropriately selected depending on the host cell. In culture, conditions such as temperature, pH of the medium, and incubation time should be appropriately adjusted to be suitable for cell growth and mass production of proteins. Host cells that can be transformed with the expression vector according to the present invention include prokaryotic cells, and a host with high expression efficiency of introduced DNA and a high expression efficiency of introduced DNA is usually used. Bacteria, for example, known prokaryotic hosts such as Escherichia, Pseudomonas, Bacillus, Streptomyces, are examples of host cells that can be used. Preferably E. coli can be used. Expression of the peptide can be induced using inducer IPTG, and induction time can be controlled to maximize the amount of protein. In the present invention, recombinantly produced peptides can be recovered from medium or cell lysate. Cells used for peptide expression can be disrupted by a variety of physical or chemical means, such as freeze-thaw repeats, sonication, mechanical disruption or cell digestion, and are isolated by conventional biochemical separation techniques. Purification is possible (Sambrook et al., Molecular Cloning: A laborarory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989; Deuscher, M., Guide to Protein Purification Methods Enzymology, Vol. 182. Academic Press. Inc., San Diego, CA, 1990). Electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (ion exchange chromatography, affinity chromatography, immunosorbent affinity chromatography, reverse phase HPLC, gel permeation HPLC), isoelectric focus and various variations and combinations thereof Including but not limited to.

In another aspect, the present invention provides a method for preparing a bead array comprising: binding the fusion polypeptide to beads for beads array; Reacting the beads to which the fusion polypeptide is bound with a sample; Reacting the sample with a marker labeled secondary antibody; A method of detecting HPV antibodies in a sample by reacting the secondary antibody with a specific binding agent of the marker to which a fluorescent substance is attached and measuring a fluorescence value derived from a bead and a fluorescence value derived from a specific binding agent of a marker are provided. . The bead array beads may be glutathione-casein (GC) beads, the marker may be biotin and the specific binding agent of the marker may be streptavidin, and the fluorescent material may be fluorescein, isothiocia. Nate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde or fluorescarmine. The bead array may be a multi-bead array, in the specific embodiment of the present invention was used luminex analysis.

The method according to the present invention comprises an amino acid sequence of glutathione S-transferase (GST) at its N terminus or an active fragment thereof; The amino acid sequence of the simian virus 40 large T-antigen at its C terminus or an active fragment thereof; And a recombinant HPV antigen, which is a fusion polypeptide comprising an amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen, or an active fragment thereof, to beads for beads array. Steps.

Luminex beads may be used as beads for the bead array. The beads are not particularly limited as long as they can be used in a multi-bead array method, and glutathione-casein (GC) beads in which glutathione-casein (GC) is additionally bound to the beads may be used. Glutathione-casein beads can be prepared by a variety of methods known in the art or can be purchased and used. According to a specific embodiment of the present invention, after blocking the cysteine residue of casein with N-ethylmaleimide (NEM), a heterobifunctional cross-linker sulfo-succinimidyl-4- (P-maleimidophenyl) -butyrate (sulfo- SMPB) was added to form casein-maleimidophenyl-butyrate, which can react with thiol groups, and to form glutathione-casein (GC) by reacting with thiol residues of glutathione cystain. Glutathione-casein beads were prepared by combining terminal amines of glutathione-casein (GC) with carboxyl groups of the beads.

Since the beads for the multiple bead array can be distinguished up to 100 types by color, a specific antigen is attached to the beads of a specific color (number), and a plurality of bead mixtures are mixed to perform a reaction, and then a multiple bead array analyzer (for example, Luminex By measuring the color of each bead and the reaction amount of the antigenic antibody on the surface of the bead simultaneously, several antibodies can be measured simultaneously, including HPV 6 L1 antibody, HPV11 L1 antibody, HPV16 L1 antibody or HPV18 L1 antibody. Therefore, not only can a small sample be analyzed, but a single experiment can replace several experiments, saving time and labor.

In addition, the method according to the invention comprises the step of reacting the beads with the fusion polypeptide is bound to the sample. The sample may include individuals that may be infected by HPV (eg mammals such as humans, livestock (eg cattle, horses, pigs, sheep and goats) and pets (eg cats and dogs)). It comes from an individual. Samples are included as long as they can contain HPV antibodies, such as serum and cells. The fusion polypeptide antigens undergo antigen-antibody reactions with HPV 6 L1 antibodies, HPV11 L1 antibodies, HPV16 L1 antibodies and HPV18 L1 antibodies in the sample.

In another aspect, the present invention is the step of reacting the sample with a marker-labeled secondary antibody reacting the secondary antibody with a specific binding agent of the marker to which the fluorescent material is attached and the fluorescence value from the beads and the specific binding agent of the marker Detecting the HPV antibody in the sample by measuring the fluorescence value of the sample. The marker may be biotin and the specific binding agent of the marker may be streptavidin.

The secondary antibody specifically binds HPV 6 L1 antibody, HPV11 L1 antibody, HPV16 L1 antibody and HPV18 L1 antibody in the sample, and biotin bound to the secondary antibody specifically binds to streptavidin (or avidin). Fluorescence is expressed in the fluorescent material bound to streptavidin. The fluorescent material may be, for example, but not limited to, fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde or fluorescamine. Various known fluorescent materials can be used.

The fluorescence value derived from the beads (color of each bead) and the fluorescence value derived from the specific binding agent of the marker were measured together to determine the reaction amount of the antigen antibody. The presence of and the titer of the antibody can be detected accurately. The titer of an antibody is measured by setting the cutoff value of a fluorescence value.

In a specific embodiment of the present invention, the HPV antigen is the amino acid sequence of glutathione S-transferase (GST) at the N terminus or an active fragment thereof, Simian virus 40 large T antigen at the C terminus (simian virus 40 By fusion with the amino acid sequence of large T-antigen or its active fragments, recombinant HPV antigens can be isolated and purified in high purity and effectively applied to beads for bead arrays without affecting the activity that can specifically bind to HPV antibodies. It is possible to attach uniformly and determine whether the recombinant HPV antigen is well attached to the beads through the Simian virus 40 large T antigen, whether the amount of attachment is always the same, and whether the degree of attachment to the beads among the four HPV antigens is uniform. HPV antibodies, including HPV 6 L1 antibody, HPV11 L1 antibody, HPV16 L1 antibody or HPV18 L1 antibody, can be screened with high sensitivity and accuracy. Ninghal could.

In another aspect, the present invention provides an amino acid sequence of glutathione S-transferase (GST) at the N-terminus or an amino acid of simian virus 40 large T-antigen at the C-terminus of active fragment thereof. HPV for bead arrays comprising a fusion polypeptide comprising an amino acid sequence of an HPV L1 antigen selected from the group consisting of sequences or active fragments thereof and HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or active fragments thereof An antibody detection kit is provided.

Using the present invention, it is possible to isolate and purify recombinant HPV antigens with high purity and effectively and uniformly attach them to beads for beads array without affecting the activity that can specifically bind to HPV antibodies. Internal HPV 6, 11, 16 and 18 antibodies can be detected in combination. The antibody titer can be used to determine the inoculation time of the HPV vaccine, and can be used to measure the duration of defense after vaccination.

FIG. 1 shows plasmid DNA isolated from E. coli DH5α transformed with pGEX4T-3 vector inserted with SV40 large T antigen to confirm that the SV40 large T antigen oligomer is correctly inserted into the expression vector pGEX4T-3. , After digestion with restriction enzyme Sal I, electrophoresis of pGEX4T-3 digested with Sal I with a DNA size marker on a 1% agarose gel.
2 is a cleavage map showing an mpGEX4T-3 / HPV6 L1 vector.
3 is a cleavage map showing an mpGEX4T-3 / HPV11 L1 vector.
4 is a cleavage map showing an mpGEX4T-3 / HPV16 L1 vector.
5 is a cleavage map showing an mpGEX4T-3 / HPV18 L1 vector.
6 shows recombinant strain E. coli ^{BL21 Gen-X TM / mpGEX4T-} 3 / HPV 6L1, E. coli ^{BL21 Gen-X TM / mpGEX4T-} 3 / HPV11L1, E. coli ^{BL21 Gen-X TM / mpGEX4T-} 3 / HPV16L1 and E. coli HPV 6 L1 antigen fusion polypeptide, HPV 11 L1 antigen fusion polypeptide, HPV 16 L1 antigen fusion polypeptide, HPV 18 L1 antigen fusion polypeptide expressed from BL21 Gen-X ^TM / mpGEX4T-3 / HPV18L1 Western blot using rabbit anti-GST antibody is shown.
7 shows recombinant strain E. coli The blotting polypeptide expressed from BL21 Gen-X ^™ / mpGEX4T-3 / HPV16L1 was expressed by Western blot using a mouse anti-HPV16 L1 antibody.
8 shows recombinant strain E. coli The blotting polypeptide of HPV 18 L1 antigen expressed from BL21 Gen-X ^™ / mpGEX4T-3 / HPV18L1 was shown by Western blot using mouse anti-HPV18 L1 antibody.
9 and 10 show standard quantification curves using HPV 16 L1 antigen and HPV18 L1 antigen by diluting HPV 16 antibody and HPV18 antibody in sequence.
Figure 11 shows the actual amount of HPV antibody in the blood using the HPV16 L1 antigen and HPV18 L1 antigen of the present invention after the blood was collected after vaccination in the group vaccinated with the bivalent HPV vaccine and Placebo vaccine. It is a result of a measurement.

Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

Example 1 Construction of a Modified Expression Vector Tagged with SV40

To confirm the binding of the microbeads and the fusion polypeptides later, the pGEX4t-3 expression vector was modified to tag the antigen with 11 amino acids of the SV40 large T antigen.

First, SEQ ID NO: 1 sense DNA oligomer (SV40S) encoding 11 amino acid sequences of the SV40 large T antigen and SEQ ID NO: 2 antisense DNA oligomer (SV40AS) complementary to the base were prepared, respectively. The SEQ ID NO: 1 oligomer was synthesized to include restriction enzyme Sal I cleavage site, and the SEQ ID NO: 2 oligomer included restriction enzyme Not I cleavage site. Each of the synthesized oligomers was reacted at 90 ° C. for 4 minutes under annealing buffer, followed by reaction at 70 ° C. for 10 minutes and 10 ° C. for 2 hours. The annealed SV40 large T antigen oligomer was inserted into the expression vector pGEX4T-3 digested with restriction enzymes Sal I and Not I and ligated for 3 hours at room temperature using T4 DNA ligase, followed by Escherichia coli E. coli. DH5α was transformed (Sambrook, J. et al., 1989, Molecular cloning, a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press).

SEQ ID NO: 1 sense DNA oligomer (SV40S):

5'- TC GAC AAA CCT CCC ACA CCT CCC CCT GAA CCT GAA ACA GC -3 '

SEQ ID NO: 2 antisense DNA oligomer (SV40AS):

5'- GGCCGC TGT TTC AGG TTC AGG GGG AGG TGT GGG AGG TTT G -3 '

Plasmid DNA was isolated from the transformants, digested with restriction enzyme Sal I, and electrophoresed with DNA size markers and pGEX4T-3 digested with Sal I on a 1% agarose gel to obtain SV40 large T antigen oligomer. It was again confirmed that it was correctly inserted in the expression vector (FIG. 1). PGEX4T-3 modified with the DNA sequence encoding the SV40 large T antigen constructed as above was named mpGEX4T-3.

Example 2 Construction of Expression Vectors for Expression of HPV 6 L1, HPV 11 L1, HPV 16 L1 and HPV 18 L1 Genes

Recombinant plasmid containing L1 genes from recombinant plasmid harboring full genome of HPV 6, HPV 11, HPV 16 and HPV 18 sold from Germany (mpGEX4T-3 / HPV 6 L1, mpGEX4T-3 / HPV11 L1, mpGEX4T) -3 / HPV16 L1 and mpGEX4T-3 / HPV18 L1) were constructed as follows.

First, the SEQ ID NO: 3 primer (HPV6L1F) (5 'terminal primer) encoding the N-terminal amino acid sequence from the nucleotide sequence of the HPV 6 L1 gene to obtain HPV 6 L1, HPV 11 L1, HPV 16 L1 and HPV 18 L1 gene SEQ ID NO: 4 primer (HPV6L1R) complementary to the DNA base encoding the C-terminal amino acid sequence (3 'terminal primer) SEQ ID NO: 5 primer (HPV11L1F) encoding the N-terminal amino acid sequence from the nucleotide sequence of the HPV 11 L1 gene ( SEQ ID NO: 6 primer (HPV11L1R) (3 'terminal primer) sequence complementary to the DNA base encoding the C-terminal amino acid sequence) and the C-terminal amino acid sequence Salt of HPV 18 L1 gene with SEQ ID NO: 8 primer (HPV16L1R) (3 'terminal primer) complementary to 7 primer (HPV16L1F) (5' terminal primer) and DNA base encoding C-terminal amino acid sequence SEQ ID NO: 9 primer (HPV18L1F) (5 'terminal primer) encoding the N-terminal amino acid sequence from the sequence and SEQ ID NO: 10 primer (HPV18L1R) (3' terminal primer) complementary to the DNA base encoding the C-terminal amino acid sequence Were produced respectively.

Each HPV L1 gene was amplified using the prepared primers. The primers SEQ ID NO: 3, 5, 7, 9 were synthesized to include restriction enzyme Eco RI or Bgl II cleavage sites, and SEQ ID NO: 4, 6, 8, 10 primers containing restriction enzyme Sal I cleavage sites.

Each PCR was a mixed composition consisting of 0.2 μg HPV plasmid DNA, 10 pmole 5'-terminal and 3'-terminal primers, 200 μM dNTPs, 10X Accuprime DNA polymerase buffer and 2.5 U Accuprime DNA polymerase (invitrogen). After reacting for 3 minutes at 95 ℃ 30 times at 95 ℃ 30 seconds, 30 seconds at 60 ℃, 90 times at 68 ℃ 90 seconds, and then reacted for 5 minutes at the last 68 ℃.

SEQ ID NO: 3 Primer (HPV6L1F):

5'-NNNNN GAATTC AATGTGGCGGCCTAGCGACAG-3 '(includes Eco RI cut)

SEQ ID NO: 4 Primer (HPV6L1R):

5'-GCATGA GTCGAC CCTTTTAGTTTTGGCGCGC-3 'with Sal I cut

SEQ ID NO: 5 Primer (HPV11L1F):

5'-GCAGTC GAATTC GTGGCGGCCTAGCGACAGCACA-3 '(includes Eco RI cut)

SEQ ID NO: 6 Primer (HPV11L1R):

5'-NNNNN GTCGAC CTTTTTGGTTTTGGTACGTTTTCGTTT-3 '(including Sal I cut)

SEQ ID NO: 7 Primer (HPV16L1F):

5'-NNNNN AGATCT ATGCAGGTGACTTTTATTTACATCCTA-3 '(including Bgl II cleavage site)

SEQ ID NO: 8 Primer (HPV16L1R):

5'-GCATGA GTCGAC CAGCTTACGTTTTTTGCGTTTAGC-3 '(Including Sal I cut)

SEQ ID NO: 9 Primer (HPV18L1F):

5'-NNNNN GAATTC AATGTGCCTGTATACACGGGTCCTG-3 '(includes Eco RI cut)

SEQ ID NO: 10 Primer (HPV18L1R):

5'-GCATGA GTCGAC CTTCCTGGCACGTACACGGAC-3 '(includes Sal I cleavage)

Electrophoresis on 1% agarose gels with DNA size markers confirmed the presence of each band at about 1.5 kb. After the PCR reaction mixture was electrophoresed on a 1% agarose gel, the DNA product of about 1.5 kb amplified by PCR was recovered by using a PCR quick-spin ^TM PCR Product Purification Kit (Intron, Korea). The recovered HPV 6, HPV 11, HPV 18 DNA was digested with restriction enzymes Eco RI and Sal I, and HPV 16 DNA was digested with restriction enzymes Bgl II and Sal I, respectively, and the gene fragments were purified and recovered, respectively. The purified gene fragments were inserted into the expression vector mpGEX4T-3 digested with the same restriction enzyme, and then ligated for 3 hours at room temperature using T4 DNA ligase, followed by transduction to E. coli BL21 Gen-X ^TM . Switched. (For the production of mpGEX4T-3 / HPV16 L1, the restriction enzymes Bgl II and Bam HI had the same annealing sequence, so that mpGEX4T-3 was cut into Bam HI and HPV 16 L1 was cut into Bgl II.) Plasmid DNA was isolated, digested with the above restriction enzymes, and electrophoresed with DNA size markers on a 1% agarose gel to confirm that each gene was correctly inserted into the expression vector. The expression vector constructed for the expression of the HPV 6 L1 gene constructed as described above is mpGEX4T-3 / HPV6L1 (Fig. 2), and the expression vector constructed for the expression of the HPV 11 L1 gene was mpGEX4T-3 / HPV11L1 (Fig. 3), the expression vector constructed for the expression of HPV 16 L1 gene was named mpGEX4T-3 / HPV16L1 (FIG. 4). The expression vector constructed for the expression of HPV 18 L1 gene was named mpGEX4T-3 / HPV18L1 (FIG. 5). ).

Example 3: Expression and Purification of Fusion Polypeptides Including HPV 6 L1, HPV 11 L1, HPV 16 L1, HPV 18 L1

E. coli BL21 Gen-X ^TM / mpGEX4T-3 / HPV 6L1, E. coli BL21 Gen-X ^TM / mpGEX4T-3 / HPV11L1, E. coli BL21 Gen-X ^TM / mpGEX4T-3 / HPV16L1 and ^{E. coli BL21 Gen-X TM /} mpGEX4T-3 / from the GST at the N-terminal HPV18L1, HPV 6 L1 antigen of SV40 fusion, HPV11 L1 antigen, HPV16 L1 antigen, respectively antigen expressed by HPV18 L1 to C-terminal Western blot using rabbit anti-GST antibody, mouse anti-HPV6 L1 antibody, mouse anti-HPV11 L1 antibody, mouse anti-HPV16 L1 antibody or mouse anti-HPV18 L1 antibody, and KT3 antibody as the first antibody Expression was confirmed. The results were confirmed through FIGS. 6 to 8. The expressed protein was then purified as follows.

E. coli BL21 Gen-X ^TM with recombinant plasmid was inoculated in LB liquid medium with 100 μg / μl ampicillin and incubated at 37 ° C. for 16 hours, followed by 500ul of LB liquid medium with 100 μg / μl Ampicillin. Inoculated in 100ml and incubated at 37 ℃. When the absorbance at 600 nm was about 0.4, IPTG (isopropyl β-D-galactopyranoside) was added to a final concentration of 1.0 mM and incubated for 3 hours to induce protein expression. Cells (1.4 g / wet weight) were recovered by centrifugation at 6,000 rpm for 15 minutes and then 5 ml of sonication buffer (50 mM Tris-HCl [1] containing Complete ^TM Protease Inhibitor Cocktail (Santa Cruz Biotechnology) [ pH8.0], 150 mM NaCl, 5 mM EDTA), and then the final concentration of 0.1mg / ml lysozyme is added and lysed at 4 ° C for 1 hour. After crushing by ultrasound, 1% triton x-100 was added and reacted at 4 ° C. for 1 hour, and centrifuged at 14,000 rpm for 15 minutes to remove E. coli cell debris. Next, the supernatant was finally purified by affinity chromatography using Glutathione Sepharose ™ 4B (GE Healthcare).

Example 4 Binding the Purified Fusion Polypeptide to Casein-Coupled Beads

4-1.Glutathione-casein (GC) manufacture

Blocking cysteine residues of casein with N-ethylmaleimide (NEM) and then adding thiol by adding sulfo-succinimidyl-4- (P-maleimidophenyl) -butyrate (sulfo-SMPB), a heterobifunctional cross-linker. ) Casein-maleimidophenyl-butyrate was formed. After removing residual NEM and sulfo-SMPB using PD10 column, glutathione-casein was formed by reaction with thiol residue of glutathione cystain. The remaining glutathione was removed using the PD10 column again.

4-2. Luminex bead with GC

In order to produce Glutathione-casein (GC) beads combined with the terminal amines of GC and the carboxyl groups of beads, 200 μl activation buffer [0.1] was used. mol / L sodium phosphate, pH 6.2] twice, and then shaded with 25 μl of 50 mg / mL of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS). The beads were activated for 20 minutes at room temperature. Activated beads were washed twice with 1 ml of coupling buffer [2-morpholinoethanesulfonic acid, 50 mmol / L, pH 5.0], the upper layer was removed, and then suspended with 250 ml of 250 mg / L, GC solution. After coupling at room temperature for 2 hours. Then, washed twice with 1 ml of washing buffer [phosphate-buffered saline (PBS), 50 mmol / L Tris, 0.5 mL / L Tween 20, pH 7.4], and then storage solution [PBS, pH 7.4, containing 1 g / L casein and 0.5 g / L sodium azide] and stored at 4 ℃ shaded.

4-3. Binding Polypeptides to GC Beads

The produced fusion polypeptide was diluted with 1 g / L of casein buffer [1 g / L casein in PBS, pH 7.4] and then reacted by shielding 3,000 GC beads at room temperature. After 1 hour, washed three times with casein buffer solution.

Example 5 Multiplex Luminex Analysis

HPV 16 antibodies (Abnova, MAB1616) and HPV18 antibodies (Ab31492) were each diluted 4,000-500 times in sequence to confirm standard quantitation curves using HPV 16 L1 antigen and HPV18 L1 antigen first (FIGS. 9 and 10).

Subsequently, blood was collected three months after vaccination in the group vaccinated with the bivalent HPV vaccine (Serbarix, GSK) and Placebo vaccine, and the serum was isolated using the developed HPV16 L1 antigen and HPV18 L1 antigen. The amount of HPV antibody in the blood was measured. The bead mixture to which the fusion polypeptide was bound was shielded for 2 hours in diluted wells and 96 well plates and reacted at room temperature. Wash three times with 100 μl casein buffer and dilute biotin-bound secondary antibody (goat anti-human IgA, IgM, IgG (H + L)) to 1: 1,000 for 30 minutes. Finally, the reaction was performed for 30 minutes by the addition of streptavidin-R-phycoerythrin, a color developing reagent, and median fluorescence intensity (MFI) was measured by a Luminex analyzer.

The results are shown in FIG. A total of 12 subjects (7 bivalent HPV vaccinates and 5 Placebo vaccinates) were tested. All of the vaccinated antibodies formed HPV 16, but only 5 out of 7 antibodies to HPV 18 were detected. Could.

<110> Gyngen Bio CO., LTD.          DIATECH KOREA CO., LTD. <120> Screening method of Human Papillomavirus antibody using fusion          polypeptide HPV antigen <130> PA110192 / KR <150> KR10-2010-0025690 <151> 2010-03-23 <160> 14 <170> KopatentIn 1.71 <210> 1 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> SV40 Large T antigen sense <400> 1 tcgacaaacc tcccacacct ccccctgaac ctgaaacagc 40 <210> 2 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> SV40 Large T antigen antisense <400> 2 ggccgctgtt tcaggttcag ggggaggtgt gggaggttt 39 <210> 3 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> primer HPV6L1F <400> 3 nnnnngaatt caatgtggcg gcctagcgac ag 32 <210> 4 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> primer HPV6L1R <400> 4 gcatgagtcg acccttttag ttttggcgcg c 31 <210> 5 <211> 34 <212> DNA <213> Artificial Sequence <220> <223> primer HPV11L1F <400> 5 gcagtcgaat tcgtggcggc ctagcgacag caca 34 <210> 6 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> primer HPV11L1R <400> 6 nnnnngtcga cctttttggt tttggtacgt tttcgttt 38 <210> 7 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> primer HPV16L1F <400> 7 nnnnnagatc tatgcaggtg acttttattt acatccta 38 <210> 8 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer HPV16L1R <400> 8 gcatgagtcg accagcttac gttttttgcg tttagc 36 <210> 9 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> primer HPV18L1F <400> 9 nnnnngaatt caatgtgcct gtatacacgg gtcctg 36 <210> 10 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> primer HPV18L1R <400> 10 gcatgagtcg accttcctgg cacgtacacg gac 33 <210> 11 <211> 746 <212> PRT <213> Artificial Sequence <220> 223 fusion polypeptide HPV 6 L1 <400> 11 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro   1 5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu              20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu          35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys      50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn  65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu                  85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser             100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu         115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn     130 135 140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu                 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr             180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala         195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg     210 215 220 Gly Ser Pro Asn Ser Met Trp Arg Pro Ser Asp Ser Thr Val Tyr Val 225 230 235 240 Pro Pro Pro Asn Pro Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val                 245 250 255 Thr Arg Thr Asn Ile Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala             260 265 270 Val Gly His Pro Tyr Phe Ser Ile Lys Arg Ala Asn Lys Thr Val Val         275 280 285 Pro Lys Val Ser Gly Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro     290 295 300 Asp Pro Asn Lys Phe Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr 305 310 315 320 Thr Gln Arg Leu Val Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly                 325 330 335 Gln Pro Leu Gly Val Gly Val Ser Gly His Pro Phe Leu Asn Lys Tyr             340 345 350 Asp Asp Val Glu Asn Ser Gly Ser Gly Gly Asn Pro Gly Gln Asp Asn         355 360 365 Arg Val Asn Val Gly Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val     370 375 380 Gly Cys Ala Pro Pro Leu Gly Glu His Trp Gly Lys Gly Lys Gln Cys 385 390 395 400 Thr Asn Thr Pro Val Gln Ala Gly Asp Cys Pro Pro Leu Glu Leu Ile                 405 410 415 Thr Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala             420 425 430 Met Asn Phe Ala Asp Leu Gln Thr Asn Lys Ser Asp Val Pro Ile Asp         435 440 445 Ile Cys Gly Thr Thr Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala     450 455 460 Asp Pro Tyr Gly Asp Arg Leu Phe Phe Phe Leu Arg Lys Glu Gln Met 465 470 475 480 Phe Ala Arg His Phe Phe Asn Arg Ala Gly Glu Val Gly Glu Pro Val                 485 490 495 Pro Asp Thr Leu Ile Ile Lys Gly Ser Gly Asn Arg Thr Ser Val Gly             500 505 510 Ser Ser Ile Tyr Val Asn Thr Pro Ser Gly Ser Leu Val Ser Ser Glu         515 520 525 Ala Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His     530 535 540 Asn Asn Gly Ile Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp 545 550 555 560 Thr Thr Arg Ser Thr Asn Met Thr Leu Cys Ala Ser Val Thr Thr Ser                 565 570 575 Ser Thr Tyr Thr Asn Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu             580 585 590 Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser         595 600 605 Ala Glu Val Met Ala Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu     610 615 620 Asp Trp Asn Phe Gly Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp 625 630 635 640 Thr Tyr Arg Tyr Val Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr                 645 650 655 Pro Glu Lys Glu Lys Pro Asp Pro Tyr Lys Asn Leu Ser Phe Trp Glu             660 665 670 Val Asn Leu Lys Glu Lys Phe Ser Ser Glu Leu Asp Gln Tyr Pro Leu         675 680 685 Gly Arg Lys Phe Leu Leu Gln Ser Gly Tyr Arg Gly Arg Ser Ser Ile     690 695 700 Arg Thr Gly Val Lys Arg Pro Ala Val Ser Lys Ala Ser Ala Ala Pro 705 710 715 720 Lys Arg Lys Arg Ala Lys Thr Lys Arg Val Asp Lys Pro Pro Thr Pro                 725 730 735 Pro Pro Glu Pro Glu Thr Ala Ala Ala Ser             740 745 <210> 12 <211> 746 <212> PRT <213> Artificial Sequence <220> <223> fusion polypeptide HPV 11 L1 <400> 12 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro   1 5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu              20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu          35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys      50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn  65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu                  85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser             100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu         115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn     130 135 140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu                 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr             180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala         195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg     210 215 220 Gly Ser Pro Asn Ser Trp Arg Pro Ser Asp Ser Thr Val Tyr Val Pro 225 230 235 240 Pro Pro Asn Pro Val Ser Lys Val Val Ala Thr Asp Ala Tyr Val Lys                 245 250 255 Arg Thr Asn Ile Phe Tyr His Ala Ser Ser Ser Arg Leu Leu Ala Val             260 265 270 Gly His Pro Tyr Tyr Ser Ile Lys Lys Val Asn Lys Thr Val Val Pro         275 280 285 Lys Val Ser Gly Tyr Gln Tyr Arg Val Phe Lys Val Val Leu Pro Asp     290 295 300 Pro Asn Lys Phe Ala Leu Pro Asp Ser Ser Leu Phe Asp Pro Thr Thr 305 310 315 320 Gln Arg Leu Val Trp Ala Cys Thr Gly Leu Glu Val Gly Arg Gly Gln                 325 330 335 Pro Leu Gly Val Gly Val Ser Gly His Pro Leu Leu Asn Lys Tyr Asp             340 345 350 Asp Val Glu Asn Ser Gly Gly Tyr Gly Gly Asn Pro Gly Gln Asp Asn         355 360 365 Arg Val Asn Val Gly Met Asp Tyr Lys Gln Thr Gln Leu Cys Met Val     370 375 380 Gly Cys Ala Pro Pro Leu Gly Glu His Trp Gly Lys Gly Thr Gln Cys 385 390 395 400 Ser Asn Thr Ser Val Gln Asn Gly Asp Cys Pro Pro Leu Glu Leu Ile                 405 410 415 Thr Ser Val Ile Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala             420 425 430 Met Asn Phe Ala Asp Leu Gln Thr Asn Lys Ser Asp Val Pro Leu Asp         435 440 445 Ile Cys Gly Thr Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ala Ala     450 455 460 Asp Pro Tyr Gly Asp Arg Leu Phe Phe Tyr Leu Arg Lys Glu Gln Met 465 470 475 480 Phe Ala Arg His Phe Phe Asn Arg Ala Gly Thr Val Gly Glu Pro Val                 485 490 495 Pro Asp Asp Leu Leu Val Lys Gly Gly Asn Asn Arg Ser Ser Val Ala             500 505 510 Ser Ser Ile Tyr Val His Thr Pro Ser Gly Ser Leu Val Ser Ser Glu         515 520 525 Ala Gln Leu Phe Asn Lys Pro Tyr Trp Leu Gln Lys Ala Gln Gly His     530 535 540 Asn Asn Gly Ile Cys Trp Gly Asn His Leu Phe Val Thr Val Val Asp 545 550 555 560 Thr Thr Arg Ser Thr Asn Met Thr Leu Cys Ala Ser Val Ser Lys Ser                 565 570 575 Ala Thr Tyr Thr Asn Ser Asp Tyr Lys Glu Tyr Met Arg His Val Glu             580 585 590 Glu Phe Asp Leu Gln Phe Ile Phe Gln Leu Cys Ser Ile Thr Leu Ser         595 600 605 Ala Glu Val Met Ala Tyr Ile His Thr Met Asn Pro Ser Val Leu Glu     610 615 620 Asp Trp Asn Phe Gly Leu Ser Pro Pro Pro Asn Gly Thr Leu Glu Asp 625 630 635 640 Thr Tyr Arg Tyr Val Gln Ser Gln Ala Ile Thr Cys Gln Lys Pro Thr                 645 650 655 Pro Glu Lys Glu Lys Gln Asp Pro Tyr Lys Asp Met Ser Phe Trp Glu             660 665 670 Val Asn Leu Lys Glu Lys Phe Ser Ser Glu Leu Asp Gln Phe Pro Leu         675 680 685 Gly Arg Lys Phe Leu Leu Gln Ser Gly Tyr Arg Gly Arg Thr Ser Ala     690 695 700 Arg Thr Gly Ile Lys Arg Pro Ala Val Ser Lys Pro Ser Thr Ala Pro 705 710 715 720 Lys Arg Lys Arg Thr Lys Thr Lys Lys Val Asp Lys Pro Pro Thr Pro                 725 730 735 Pro Pro Glu Pro Glu Thr Ala Ala Ala Ser             740 745 <210> 13 <211> 774 <212> PRT <213> Artificial Sequence <220> 223 fusion polypeptide HPV 16 L1 <400> 13 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro   1 5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu              20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu          35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys      50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn  65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu                  85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser             100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu         115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn     130 135 140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu                 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr             180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala         195 200 205 Thr Phe Gly Gly Gly Asp His Xaa Pro Lys Ser Asp Leu Val Pro Arg     210 215 220 Gly Ser Met Gln Val Thr Phe Ile Tyr Ile Leu Val Ile Thr Cys Tyr 225 230 235 240 Glu Asn Asp Val Asn Val Tyr His Ile Phe Phe Gln Met Ser Leu Trp                 245 250 255 Leu Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val Pro Val Ser Lys             260 265 270 Val Val Ser Thr Asp Glu Tyr Val Ala Arg Thr Asn Ile Tyr Tyr His         275 280 285 Ala Gly Thr Ser Arg Leu Leu Ala Val Gly His Pro Tyr Phe Pro Ile     290 295 300 Lys Lys Pro Asn Asn Asn Lys Ile Leu Val Pro Lys Val Ser Gly Leu 305 310 315 320 Gln Tyr Arg Val Phe Arg Ile His Leu Pro Asp Pro Asn Lys Phe Gly                 325 330 335 Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr Gln Arg Leu Val Trp             340 345 350 Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro Leu Gly Val Gly         355 360 365 Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp Thr Glu Asn Ala     370 375 380 Ser Ala Tyr Ala Ala Asn Ala Gly Val Asp Asn Arg Glu Cys Ile Ser 385 390 395 400 Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile Gly Cys Lys Pro Pro                 405 410 415 Ile Gly Glu His Trp Gly Lys Gly Ser Pro Cys Thr Asn Val Ala Val             420 425 430 Asn Pro Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn Thr Val Ile Gln         435 440 445 Asp Gly Asp Met Val His Thr Gly Phe Gly Ala Met Asp Phe Thr Thr     450 455 460 Leu Gln Ala Asn Lys Ser Glu Val Pro Leu Asp Ile Cys Thr Ser Ile 465 470 475 480 Cys Lys Tyr Pro Asp Tyr Ile Lys Met Val Ser Glu Pro Tyr Gly Asp                 485 490 495 Ser Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe Val Arg His Leu             500 505 510 Phe Asn Arg Ala Gly Thr Val Gly Glu Asn Val Pro Asp Asp Leu Tyr         515 520 525 Ile Lys Gly Ser Gly Ser Thr Ala Asn Leu Ala Ser Ser Asn Tyr Phe     530 535 540 Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala Gln Ile Phe Asn 545 550 555 560 Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly Ile Cys                 565 570 575 Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser Thr             580 585 590 Asn Met Ser Leu Cys Ala Ala Ile Ser Thr Ser Glu Thr Thr Tyr Lys         595 600 605 Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu Glu Tyr Asp Leu     610 615 620 Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala Asp Val Met 625 630 635 640 Thr Tyr Ile His Ser Met Asn Ser Thr Ile Leu Glu Asp Trp Asn Phe                 645 650 655 Gly Leu Gln Pro Pro Pro Gly Gly Thr Leu Glu Asp Thr Tyr Arg Phe             660 665 670 Val Thr Ser Gln Ala Ile Ala Cys Gln Lys His Thr Pro Pro Ala Pro         675 680 685 Lys Glu Asp Pro Leu Lys Lys Tyr Thr Phe Trp Glu Val Asn Leu Lys     690 695 700 Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly Arg Lys Phe 705 710 715 720 Leu Leu Gln Ala Gly Leu Lys Ala Lys Pro Lys Phe Thr Leu Gly Lys                 725 730 735 Arg Lys Ala Thr Pro Thr Thr Ser Ser Thr Ser Thr Thr Ala Lys Arg             740 745 750 Lys Lys Arg Lys Leu Val Asp Lys Pro Pro Thr Pro Pro Pro Glu Pro         755 760 765 Glu Thr Ala Ala Ala Ser     770 <210> 14 <211> 814 <212> PRT <213> Artificial Sequence <220> 223 fusion polypeptide HPV 18 L1 <400> 14 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro   1 5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu              20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu          35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys      50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn  65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu                  85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser             100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu         115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn     130 135 140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu                 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr             180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala         195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg     210 215 220 Gly Ser Pro Asn Ser Met Cys Leu Tyr Thr Arg Val Leu Ile Leu His 225 230 235 240 Tyr His Leu Leu Pro Leu Tyr Gly Pro Leu Tyr His Pro Arg Pro Leu                 245 250 255 Pro Leu His Ser Ile Leu Val Tyr Met Val His Ile Ile Ile Cys Gly             260 265 270 His Tyr Ile Ile Leu Phe Leu Arg Asn Val Asn Val Phe Pro Ile Phe         275 280 285 Leu Gln Met Ala Leu Trp Arg Pro Ser Asp Asn Thr Val Tyr Leu Pro     290 295 300 Pro Pro Ser Val Ala Arg Val Val Asn Thr Asp Asp Tyr Val Thr Arg 305 310 315 320 Thr Ser Ile Phe Tyr His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly                 325 330 335 Asn Pro Tyr Phe Arg Val Pro Ala Gly Gly Gly Asn Lys Gln Asp Ile             340 345 350 Pro Lys Val Ser Ala Tyr Gln Tyr Arg Val Phe Arg Val Gln Leu Pro         355 360 365 Asp Pro Asn Lys Phe Gly Leu Pro Asp Thr Ser Ile Tyr Asn Pro Glu     370 375 380 Thr Gln Arg Leu Val Trp Ala Cys Ala Gly Val Glu Ile Gly Arg Gly 385 390 395 400 Gln Pro Leu Gly Val Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu                 405 410 415 Asp Asp Thr Glu Ser Ser His Ala Ala Thr Ser Asn Val Ser Glu Asp             420 425 430 Val Arg Asp Asn Val Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile         435 440 445 Leu Gly Cys Ala Pro Ala Ile Gly Glu His Trp Ala Lys Gly Thr Ala     450 455 460 Cys Lys Ser Arg Pro Leu Ser Gln Gly Asp Cys Pro Pro Leu Glu Leu 465 470 475 480 Lys Asn Thr Val Leu Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly                 485 490 495 Ala Met Asp Phe Ser Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu             500 505 510 Asp Ile Cys Gln Ser Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser         515 520 525 Ala Asp Pro Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln     530 535 540 Leu Phe Ala Arg His Phe Trp Asn Arg Ala Gly Thr Met Gly Asp Thr 545 550 555 560 Val Pro Gln Ser Leu Tyr Ile Lys Gly Thr Gly Met Arg Ala Ser Pro                 565 570 575 Gly Ser Cys Val Tyr Ser Pro Ser Pro Ser Gly Ser Ile Val Thr Ser             580 585 590 Asp Ser Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly         595 600 605 His Asn Asn Gly Val Cys Trp His Asn Gln Leu Phe Val Thr Val Val     610 615 620 Asp Thr Thr Arg Ser Thr Asn Leu Thr Ile Cys Ala Ser Thr Gln Ser 625 630 635 640 Pro Val Pro Gly Gln Tyr Asp Ala Thr Lys Phe Lys Gln Tyr Ser Arg                 645 650 655 His Val Glu Glu Tyr Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Ile             660 665 670 Thr Leu Thr Ala Asp Val Met Ser Tyr Ile His Ser Met Asn Ser Ser         675 680 685 Ile Leu Glu Asp Trp Asn Phe Gly Val Pro Pro Pro Thr Thr Ser     690 695 700 Leu Val Asp Thr Tyr Arg Phe Val Gln Ser Val Ala Ile Thr Cys Gln 705 710 715 720 Lys Asp Ala Ala Pro Ala Glu Asn Lys Asp Pro Tyr Asp Lys Leu Lys                 725 730 735 Phe Trp Asn Val Asp Leu Lys Glu Lys Phe Ser Leu Asp Leu Asp Gln             740 745 750 Tyr Pro Leu Gly Arg Lys Phe Leu Val Gln Ala Gly Leu Arg Arg Lys         755 760 765 Pro Thr Ile Gly Pro Arg Lys Arg Ser Ala Pro Ser Ala Thr Thr Ser     770 775 780 Ser Lys Pro Ala Lys Arg Val Arg Val Arg Ala Arg Lys Val Asp Lys 785 790 795 800 Pro Pro Thr Pro Pro Pro Glu Pro Glu Thr Ala Ala Ala Ser                 805 810

Claims (15)

Amino acid sequence of glutathione S-transferase (GST) at its N-terminus or active fragment thereof
The amino acid sequence of the simian virus 40 large T-antigen at its C terminus or an active fragment thereof; and
A fusion polypeptide comprising the amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or active fragment thereof.
The fusion polypeptide of claim 1, wherein the amino acid sequence of the fusion polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-14.
Polynucleotides encoding the following fusion polypeptides:
Amino acid sequence of glutathione S-transferase (GST) at its N-terminus or active fragment thereof
The amino acid sequence of the simian virus 40 large T-antigen at its C terminus or an active fragment thereof; and
A fusion polypeptide comprising the amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or active fragment thereof.
The polynucleotide encoding the amino acid sequence of the Simian virus 40 large T antigen or an active fragment thereof according to claim 3, wherein the double-stranded polynucleotide consisting of SEQ ID NO: 1 and SEQ ID NO: 2 is cleaved with Sal I and Not I restriction enzymes. One, polynucleotide.
The polynucleotide encoding the amino acid sequence of the HPV 6 L1 antigen or an active fragment thereof according to claim 3, wherein the polynucleotide amplified from the HPV 6 genome using a primer set of SEQ ID NO: 3 and SEQ ID NO: 4 is determined by Eco RI and Sal. A polynucleotide cut by I restriction enzyme.
According to claim 3, wherein the polynucleotide encoding the amino acid sequence of the HPV 11 L1 antigen or active fragments thereof are polynucleotides Eco RI and Sal I amplified from the HPV 11 genome using a primer set of SEQ ID NO: 5 and SEQ ID NO: 6 Polynucleotide cut by restriction enzyme.
The polynucleotide Bgl II and Sal I of claim 3, wherein the polynucleotide encoding the amino acid sequence of the HPV 16 L1 antigen or an active fragment thereof is amplified from the HPV 16 genome using a primer set of SEQ ID NO: 7 and SEQ ID NO: 8 Polynucleotide cut by restriction enzyme.
According to claim 3, wherein the polynucleotide encoding the amino acid sequence of the HPV 18 L1 antigen or active fragments thereof are polynucleotides Eco RI and Sal I amplified from the HPV 18 genome using a primer set of SEQ ID NO: 9 and SEQ ID NO: 10 Polynucleotide cut by restriction enzyme.
An expression vector comprising the polynucleotide of any one of claims 3 to 8.
A transformant transformed with the expression vector of claim 9.
Binding the fusion polypeptide of claim 1 to the beads for beads array;
Reacting the beads to which the fusion polypeptide is bound with a sample;
Reacting the sample with a marker labeled secondary antibody;
Reacting the secondary antibody with a specific binding agent of the marker to which a fluorescent substance is attached; And
A method for detecting HPV antibodies in a sample comprising measuring a fluorescence value derived from a bead and a fluorescence value derived from a specific binder of a marker.
The method of claim 1, wherein the beads for the bead array are glutathione-casein (GC) beads.
The method of claim 11, wherein the marker is biotin and the specific binding agent of the marker is streptavidin.
The method of claim 1, wherein the fluorescent material is fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde or fluorescamine.
Amino acid sequence of glutathione S-transferase (GST) at its N terminus or active fragment thereof at the C terminus amino acid sequence of simian virus 40 large T-antigen at its C terminus or active fragment thereof and An HPV antibody detection kit for a bead array comprising a fusion polypeptide comprising the amino acid sequence of an HPV L1 antigen selected from the group consisting of HPV 6 L1 antigen, HPV11 L1 antigen, HPV16 L1 antigen and HPV18 L1 antigen or active fragments thereof.

Images